Vasogen Inc.

Contact:
Glenn Neumann, Investor Relations
2505 Meadowvale Blvd.
Mississauga, ON, Canada L5N 5S2
tel: (905) 817-2004  fax: (905) 569-9231
www.vasogen.com / investor@vasogen.com

--------------------------------------------------------------------------------

FOR IMMEDIATE RELEASE

      Vasogen Selected to Participate in "The Horizon of New Cardiovascular
               Drugs" Panel at BIO CEO & Investor Conference 2007

Mississauga, Ontario (February 8, 2007) -- Vasogen Inc. (NASDAQ:VSGN; TSX:VAS),
a biotechnology Company focused on the research and commercial development of
technologies targeting the chronic inflammation underlying cardiovascular and
neurological disease, today announced that it has been selected to participate
in the "The Horizon of New Cardiovascular Drugs" panel at the BIO CEO & Investor
Conference 2007 to be held at the Waldorf Astoria in New York City on Monday,
February 12, 2007, at 3:30 p.m. Eastern Time.

Dr. Jay H. Kleiman, Vasogen's Chief Medical Officer and Head of Cardiovascular
Development, will be a member of the expert panel that will explore new
frontiers in cardiovascular prevention and treatment.

About Vasogen:
Vasogen is focused on the research and commercial development of technologies
targeting the chronic inflammation underlying cardiovascular and neurological
disease. Vasogen's Celacade(TM) technology is in late-stage development for the
treatment of chronic heart failure. The recently completed phase III ACCLAIM
trial assessed the impact of Celacade on reducing the risk of mortality and
morbidity in patients with Class II-IV systolic heart failure. Vasogen is also
developing a new class of drugs for the treatment of neuro-inflammatory
disorders. VP025 is the lead product candidate from this new class of drugs.

Certain  statements   contained  in  this  press  release,  the  upcoming  panel
discussion,  or elsewhere in our public  documents  constitute  "forward-looking
statements"   within  the  meaning  of  the  United  States  Private  Securities
Litigation  Reform Act of 1995 and/or  "forward-looking  information"  under the
Securities Act (Ontario).  These  statements  may include,  without  limitation,
summary  statements  relating to results of the ACCLAIM  trial in patients  with
chronic heart failure,  plans to advance the development of Celacade(TM),  plans
to fund our current activities,  statements concerning our partnering activities
and health regulatory submissions, strategy, future operations, future financial
position, future revenues,  projected costs, prospects,  plans and objectives of
management.  In some  cases,  you can  identify  forward-looking  statements  by
terminology such as "may", "will", "should", "expects", "plans",  "anticipates",
"believes",  "estimated",   "predicts",   "potential",   "continue",  "intends",
"could", or the negative of such terms or other comparable terminology.  We made
a number of assumptions in the preparation of these forward-looking  statements,
including assumptions about the nature, size and accessibility of the market for
Celacade in the treatment of chronic heart failure,  particularly in Europe, the
regulatory approval process leading to commercialization and the availability of
capital on  acceptable  terms to pursue the  development  of  Celacade,  and the
feasibility  of additional  trials.  You should not place undue  reliance on our
forward-looking  statements  which  are  subject  to a  multitude  of risks  and
uncertainties that could cause actual results, future circumstances or events to
differ materially from those projected in the forward-looking statements.  These
risks  include,  but are not limited to, the outcome of further  analysis of the
ACCLAIM  trial  results,  the  requirement  or  election  to conduct  additional
clinical trials, delays or setbacks in the regulatory approval process, securing
and maintaining  corporate  alliances,  the need for additional  capital and the
effect of capital market  conditions and other factors on capital  availability,
the potential  dilutive  effects of any  financing,  risks  associated  with the
outcome of our research  and  development  programs,  the  adequacy,  timing and
results of our clinical trials, competition,  market acceptance of our products,
the  availability of government and insurance  reimbursements  for our products,
the  strength  of  intellectual  property,  reliance on  subcontractors  and key
personnel,  losses due to fluctuations in the  U.S.-Canadian  exchange rate, and
other risks  detailed  from time to time in our public  disclosure  documents or
other  filings  with the  Canadian  and  U.S.  securities  commissions  or other
securities regulatory bodies. Additional risks and uncertainties relating to our
Company  and our  business  can be found in the "Risk  Factors"  section  of our
Annual  Information  Form and Form 20-F for the year ended November 30, 2006, as
well as in our later public filings. The forward-looking  statements are made as
of the date hereof,  and we disclaim any  intention  and have no  obligation  or
responsibility,   except  as   required   by  law,   to  update  or  revise  any
forward-looking  statements,  whether  as a result  of new  information,  future
events or otherwise. Unless otherwise indicated, numerical values indicating the
statistical  significance  ("p-values") of results included in this document are
based on analyses that do not account for endpoint multiplicity.